BACKGROUND: Prevention of meningeal recurrence achieved by intrathecal methotrexate (MTX) and systemic chemotherapy is part of standard acute lymphoblastic leukemia (ALL) treatment. Cranial irradiation has been a routine part of past protocol treatment but is currently reserved only for select subsets of patients. Central nervous system (CNS) prophylaxis may cause brain abnormalities such as intracerebral calcifications, cerebral atrophy, and white matter alterations. In addition, long-term neuropsychologic sequelae following CNS prophylaxis have been investigated marginally in children cured for ALL. METHODS: To explore possible correlations between neuroimaging findings and neuropsychologic outcome, we used detailed cognitive tests to evaluate 21 children with ALL who received cranial irradiation (range, 18-24 Gy) plus intrathecal MTX as CNS prophylaxis. All children were followed prospectively once a year by cerebral computed tomographic scan and magnetic resonance imaging. All patients had continuous complete disease remission for at least 4 years and cognitive tests were performed after neuroradiologic examinations. RESULTS: White matter abnormalities were associated with poor performance only in a task exploring visual motor integration in about 50% of patients. Intracerebral calcifications correlate with the number of intrathecal MTX doses and with low scores in total intellectual quotient, performance intellectual quotient, and significant impairment in attention and visual motor integration tests. Girls are more vulnerable to the effects of CNS prophylaxis, whereas age at treatment and radiotherapy dose are not relevant to neuropsychologic outcome. CONCLUSIONS: Our results indicate the need for careful follow-up of children's cognitive abilities because global intellectual measures often fail to detect specific disorders that may cause learning difficulties. Moreover, as the clinical implications of neuroimaging findings are often limited, periodic extensive evaluation by specific neurocognitive tests of mental abilities is recommended to detect early signs of cognitive impairment. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10997
BACKGROUND: Prevention of meningeal recurrence achieved by intrathecal methotrexate (MTX) and systemic chemotherapy is part of standard acute lymphoblastic leukemia (ALL) treatment. Cranial irradiation has been a routine part of past protocol treatment but is currently reserved only for select subsets of patients. Central nervous system (CNS) prophylaxis may cause brain abnormalities such as intracerebral calcifications, cerebral atrophy, and white matter alterations. In addition, long-term neuropsychologic sequelae following CNS prophylaxis have been investigated marginally in children cured for ALL. METHODS: To explore possible correlations between neuroimaging findings and neuropsychologic outcome, we used detailed cognitive tests to evaluate 21 children with ALL who received cranial irradiation (range, 18-24 Gy) plus intrathecal MTX as CNS prophylaxis. All children were followed prospectively once a year by cerebral computed tomographic scan and magnetic resonance imaging. All patients had continuous complete disease remission for at least 4 years and cognitive tests were performed after neuroradiologic examinations. RESULTS:White matter abnormalities were associated with poor performance only in a task exploring visual motor integration in about 50% of patients. Intracerebral calcifications correlate with the number of intrathecal MTX doses and with low scores in total intellectual quotient, performance intellectual quotient, and significant impairment in attention and visual motor integration tests. Girls are more vulnerable to the effects of CNS prophylaxis, whereas age at treatment and radiotherapy dose are not relevant to neuropsychologic outcome. CONCLUSIONS: Our results indicate the need for careful follow-up of children's cognitive abilities because global intellectual measures often fail to detect specific disorders that may cause learning difficulties. Moreover, as the clinical implications of neuroimaging findings are often limited, periodic extensive evaluation by specific neurocognitive tests of mental abilities is recommended to detect early signs of cognitive impairment. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10997
Authors: Lyndsay A Harshman; Sheila Barron; Anna M Button; Brian J Smith; Brian K Link; Charles F Lynch; Natalie L Denburg Journal: J Pediatr Psychol Date: 2012-01-23
Authors: Marc H Bornstein; Sara Scrimin; Diane L Putnick; Fabia Capello; O Maurice Haynes; Simona de Falco; Modesto Carli; Marta Pillon Journal: J Pediatr Psychol Date: 2012-02-02
Authors: Jin-Shei Lai; Corey Bregman; Frank Zelko; Cindy Nowinski; David Cella; Jennifer J Beaumont; Stewart Goldman Journal: Qual Life Res Date: 2017-04-26 Impact factor: 4.147
Authors: Chengcheng Gui; Tracy D Vannorsdall; Lawrence R Kleinberg; Ryan Assadi; Joseph A Moore; Chen Hu; Alfredo Quiñones-Hinojosa; Kristin J Redmond Journal: Neurosurgery Date: 2020-07-01 Impact factor: 4.654
Authors: Jin-Shei Lai; Zeeshan Butt; Frank Zelko; David Cella; Kevin R Krull; Mark W Kieran; Stewart Goldman Journal: J Pediatr Psychol Date: 2011-03-04
Authors: Nina S Kadan-Lottick; Pim Brouwers; David Breiger; Thomas Kaleita; James Dziura; Veronika Northrup; Lu Chen; Megan Nicoletti; Bruce Bostrom; Linda Stork; Joseph P Neglia Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544
Authors: Emilie A Steffen-Smith; Pamela L Wolters; Paul S Albert; Eva H Baker; Kim C Shimoda; Alan S Barnett; Katherine E Warren Journal: Childs Nerv Syst Date: 2008-02-22 Impact factor: 1.475